Lil­ly's Covid-19 mAb no longer au­tho­rized due to Omi­cron sub­vari­ants, FDA says

The FDA on Wednes­day an­nounced that Eli Lil­ly’s Covid-19 drug bebtelovimab is no longer au­tho­rized to treat Covid-19 be­cause of the ris­ing num­bers of two new sub­vari­ants that the drug does not work against.

The Cen­ters for Dis­ease Con­trol and Pre­ven­tion last week pub­lished new es­ti­mates that the com­bined pro­por­tion of Covid-19 cas­es caused by the Omi­cron sub­vari­ants BQ.1 and BQ.1.1 are greater than 57% na­tion­al­ly, and al­ready above 50% in all in­di­vid­ual re­gions but one.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER